[Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule BSPM XIANYANG, China, Nov. 13, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. ( Ronghua Wang, Biostar's Chairman, commenting on the announcement, stated: "We strongly believe that regaining compliance with NASDAQ's continued listing requirements is an important achievement for the Company. Having resolved this issue, we can continue focusing on]
[Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule BSPM XIANYANG, China, Nov. 13, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. ( Ronghua Wang, Biostar's Chairman, commenting on the announcement, stated: "We strongly believe that regaining compliance with NASDAQ's continued listing requirements is an important achievement for the Company. Having resolved this issue, we can continue focusing on]
[FORM 10-Q (Mark One) x September 30, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC Nevada 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321093013.htm]
[FORM 10-Q (Mark One) x September 30, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC Nevada 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321093013.htm]
[] [v360053_ex31-1.htm 2 EX-31.1] [v360053_ex31-2.htm 3 EX-31.2] [v360053_ex32-1.htm 4 EX-32.1] [v360053_ex32-2.htm 5 EX-32.2]
[] [v360053_ex31-1.htm 2 EX-31.1] [v360053_ex31-2.htm 3 EX-31.2] [v360053_ex32-1.htm 4 EX-32.1] [v360053_ex32-2.htm 5 EX-32.2]
[FORM 10-Q (Mark One) x September 30, 2013 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 ex32-2.htm 5 EX-32.2]
[FORM 10-Q (Mark One) x September 30, 2013 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 ex32-2.htm 5 EX-32.2]
[Biostar Pharmaceuticals, Regainsmpliance With NASDAQ $1.00 Minimum Bid Price Rule BSPM XIANYANG, China, Nov. 13, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, ( Ronghua Wang, Biostar's Chairman,mmenting on the announcement, stated: "We strongly believe that regainingmpliance with NASDAQ'sntinued listing requirements is an important achievement for thempany. Having resolved this issue, wenntinue focusing on maximizing shareholder value and]
[FORM 10-Q (Mark One) x September 30, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Nevada 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86- 898-6681-1730 (China)] [CERTIFICATION OF OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:November 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) cphi10qex321093013.htm]
